GLP1R and type 1 diabetes mellitus: Long-term assessment of treatment effects on DCAN could be important during therapy with glucagon-like peptide 1 receptor agonists, which improve glucose metabolic parameters in type-1 diabetes (Guyton, Jeon and Brooks, 2019) but might exacerbate DCAN impairing the HRV vagal indexes (Kumarathurai et al., 2017).